在早期试验中,所有7名与HPV有关的癌症患者的SCG细胞治疗T细胞治疗减缩了肿瘤,没有产生严重的副作用。 SCG Cell Therapy's T-cell treatment shrank tumors in all seven HPV-related cancer patients in early trials, with no serious side effects.

SCG细胞治疗为SCG142提供了早期临床数据,SCG142是一种针对与HPV有关的癌症的T细胞治疗,在2025年ESMO大会上进行了介绍。 SCG Cell Therapy presented early clinical data for SCG142, a T-cell therapy targeting HPV-related cancers, at the ESMO 2025 Congress. 在第一阶段试验中,所有7名经常或转移性HPV16/52-呈阳性的癌症患者都出现肿瘤收缩,达到100%的疾病控制率,其中4人减少了30%以上。 In a Phase I trial, all seven patients with recurrent or metastatic HPV16/52-positive cancers showed tumor shrinkage, achieving a 100% disease control rate, including four with over 30% reduction. 没有关于严重副作用的报告,这表明安全情况良好。 No serious side effects were reported, indicating a favorable safety profile. 该疗法使用改良的受体促进T细胞活动。 The therapy uses a modified receptor to boost T-cell activity. 成果支持在较大的试验中进行进一步研究。 Results support further study in larger trials. SCG还正在研制一种类似治疗与乙型肝炎有关的肝癌的疗法。 SCG is also developing a similar treatment for hepatitis B-related liver cancer. 人类免疫机能丧失病毒每年在全世界造成近700 000例癌症病例。 HPV causes nearly 700,000 cancer cases annually worldwide.